Molecular Approach to Uterine Leiomyosarcoma: LMP2-Deficient Mice as an Animal Model of Spontaneous Uterine Leiomyosarcoma
Name
Hayashi-2011-Molecular Approach to Uterine Leiomyosarcoma.pdf
Size
1.04 MB
Format
Adobe PDF
Checksum (MD5)
7445f33cd71569df1a7b0249bca3220a
Author(s)
Hayashi, Takuma
Horiuchi, Akiko
Sano, Kenji
Hiraoka, Nobuyoshi
Kanai, Yae
Shiozawa, Tanri
Tonegawa, Susumu
Konishi, Ikuo
Date Issued
January 2011
Journal
Sarcoma
Publisher
Hindawi Pub. Corp.
Citation
Takuma Hayashi, Akiko Horiuchi, Kenji Sano, et al., “Molecular Approach to Uterine Leiomyosarcoma: LMP2-Deficient Mice as an Animal Model of Spontaneous Uterine Leiomyosarcoma,” Sarcoma, vol. 2011, Article ID 476498, 6 pages, 2011.
Version
Final published version
Abstract
Uterine leiomyosarcoma (LMS) develops more often in the muscle tissue layer of the uterine body than in the uterine cervix. The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known. Importantly, a diagnostic-biomarker which distinguishes malignant LMS from benign tumor leiomyoma (LMA) is yet to be established. Accordingly, it is necessary to analyze risk factors associated with uterine LMS, in order to establish a treatment method. LMP2-deficient mice spontaneously develop uterine LMS, with a disease prevalence of ~40% by 14 months of age. We found LMP2 expression to be absent in human LMS, but present in human LMA. Therefore, defective LMP2 expression may be one of the risk factors for LMS. LMP2 is a potential diagnostic-biomarker for uterine LMS, and may be targeted-molecule for a new therapeutic approach.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Picower Institute for Learning and Memory
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1155/2011/476498
